» Articles » PMID: 38256075

Metal-Based Nanoparticles for Cardiovascular Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jan 23
PMID 38256075
Authors
Affiliations
Soon will be listed here.
Abstract

Globally, cardiovascular diseases (CVDs) are the leading cause of death and disability. While there are many therapeutic alternatives available for the management of CVDs, the majority of classic therapeutic strategies were found to be ineffective at stopping or significantly/additionally slowing the progression of these diseases, or they had unfavorable side effects. Numerous metal-based nanoparticles (NPs) have been created to overcome these limitations, demonstrating encouraging possibilities in the treatment of CVDs due to advancements in nanotechnology. Metallic nanomaterials, including gold, silver, and iron, come in various shapes, sizes, and geometries. Metallic NPs are generally smaller and have more specialized physical, chemical, and biological properties. Metal-based NPs may come in various forms, such as nanoshells, nanorods, and nanospheres, and they have been studied the most. Massive potential applications for these metal nanomaterial structures include supporting molecular imaging, serving as drug delivery systems, enhancing radiation-based anticancer therapy, supplying photothermal transforming effects for thermal therapy, and being compounds with bactericidal, fungicidal, and antiviral qualities that may be helpful for cardiovascular diseases. In this context, the present paper aims to review the applications of relevant metal and metal oxide nanoparticles in CVDs, creating an up-to-date framework that aids researchers in developing more efficient treatment strategies.

Citing Articles

Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy.

Chen Q, Yu T, Gong J, Shan H Molecules. 2025; 30(4).

PMID: 40005272 PMC: 11858567. DOI: 10.3390/molecules30040962.


Nanocurcumin in myocardial infarction therapy: emerging trends and future directions.

Lv M, Sun Q, Yu Y, Bao J Front Bioeng Biotechnol. 2025; 12():1511331.

PMID: 39845374 PMC: 11750836. DOI: 10.3389/fbioe.2024.1511331.


The future of cardiac repair: a review on cell-free nanotherapies for regenerative myocardial infarction.

Kamal N, A Heikal L, Abdallah O Drug Deliv Transl Res. 2025; .

PMID: 39833466 DOI: 10.1007/s13346-024-01763-y.


Targeting Reactive Oxygen Species for Diagnosis of Various Diseases.

Lee M, Lee D, Choi D, Kim K, Kang P J Funct Biomater. 2024; 15(12).

PMID: 39728178 PMC: 11677255. DOI: 10.3390/jfb15120378.


Nanoparticle-Based Therapies for Cardiovascular Diseases: A Literature Review of Recent Advances and Clinical Potential.

Jha G, Sharma R, Sridhar S, Hayagreev D, Sinha T, Kaur H Cureus. 2024; 16(10):e72808.

PMID: 39552990 PMC: 11569831. DOI: 10.7759/cureus.72808.


References
1.
Varna M, Xuan H, Fort E . Gold nanoparticles in cardiovascular imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017; 10(1). DOI: 10.1002/wnan.1470. View

2.
Nedkoff L, Briffa T, Zemedikun D, Herrington S, Wright F . Global Trends in Atherosclerotic Cardiovascular Disease. Clin Ther. 2023; 45(11):1087-1091. DOI: 10.1016/j.clinthera.2023.09.020. View

3.
Almatroudi A . Silver nanoparticles: synthesis, characterisation and biomedical applications. Open Life Sci. 2021; 15(1):819-839. PMC: 7747521. DOI: 10.1515/biol-2020-0094. View

4.
Dhall A, Self W . Cerium Oxide Nanoparticles: A Brief Review of Their Synthesis Methods and Biomedical Applications. Antioxidants (Basel). 2018; 7(8). PMC: 6116044. DOI: 10.3390/antiox7080097. View

5.
Arozal W, Monayo E, Barinda A, Perkasa D, Soetikno V, Nafrialdi N . Protective effects of silver nanoparticles in isoproterenol-induced myocardial infarction in rats. Front Med (Lausanne). 2022; 9:867497. PMC: 9454814. DOI: 10.3389/fmed.2022.867497. View